Manufacturer of Controlled Substances; Notice of Application, 36727-36728 [E7-12976]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 128 / Thursday, July 5, 2007 / Notices
36727
Abbott Laboratories, DBA Knoll
Pharmaceutical Co., 30 North Jefferson
Road, Whippany, New Jersey 07981,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
I and II:
Schedule
be made in writing, with the envelope
and the letter clearly marked ‘‘Privacy
Access Request.’’ Include in the request
the full name of the individual
involved, his or her current address,
date and place of birth, notarized
signature (or submitted with date and
signature under penalty of perjury), and
any other identifying number or
information which may be of assistance
in locating the record. The requester
shall also provide a return address for
transmitting the information. Access
requests shall be directed to the System
Manager listed above.
CONTESTING RECORD PROCEDURES:
The major part of this system is
exempted from this requirement
pursuant to 5 U.S.C. 552a(j)(2), (k)(1),
and (k)(2). To the extent that this system
of records is not subject to exemption,
it is subject to contest. A determination
as to exemption shall be made at the
time a request for contest is received.
Requesters shall direct their request to
the System Manager listed above, stating
clearly and concisely what information
is being contested, the reason for
contesting it, and the proposed
amendment to the information.
RECORD SOURCE CATEGORIES:
The subjects of investigations;
individuals with whom the subjects of
investigations are associated; current
and former Department of Justice
officers and employees; Federal, State,
local and foreign law enforcement and
non-law enforcement agencies; private
citizens; witnesses; informants; and
public source materials.
EXEMPTIONS CLAIMED FOR THE SYSTEM:
The Attorney General has exempted
this system from subsections (c)(3) and
(4); (d); (e)(1), (2), (3), (5) and (8); and
(g) of the Privacy Act pursuant to 5
U.S.C. 552a(j)(2). In addition, the system
has been exempted from subsections
(c)(3), (d), and (e)(1), pursuant to
subsections (k)(1) and (k)(2). Rules have
been promulgated in accordance with
the requirements of 5 U.S.C. 553(b), (c)
and (e), and have been published in the
Federal Register. See 28 CFR 16.75.
[FR Doc. E7–12992 Filed 7–3–07; 8:45 am]
BILLING CODE 4410–BD–P
DEPARTMENT OF JUSTICE
sroberts on PROD1PC70 with NOTICES
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on April 24, 2007,
VerDate Aug<31>2005
18:43 Jul 03, 2007
Jkt 211001
Drug
Schedule
Dihydromorphine (9145) ...............
Hydromorphone (9150) ................
I
II
The company plans to manufacture
bulk product and dosage units for
distribution to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than September 5, 2007.
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12957 Filed 7–3–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 18, 2007,
Aldrich Chemical Company, Inc., DBA
Isotec, 3858 Benner Road, Miamisburg,
Ohio 45342–4304, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic class of
controlled substance listed in schedule
I and II:
Drug
Schedule
Cathinone (1235) ..........................
Methcathinone (1237) ..................
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
I
I
Drug
N-Ethylamphetamine (1475) ........
N,N-Dimethylamphetamine (1480)
Aminorex (1585) ...........................
Gamma
Hydroxybutyric
Acid
(2010).
Methaqualone (2565) ...................
Ibogaine (7260) ............................
Lysergic acid dethylamide (7315)
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
2,5-Dimethoxyamphetamine
(7396).
3,4-Methylenedioxyamphetamine
(7400).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (7405).
4-Methoxyamphetamine (7411) ...
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
N-Ethyl-1-phenylcyclohexylamine
(7455).
Dihydromorphine (9145) ...............
Normorphine (9313) .....................
Acetylmethadol (9601) .................
Alphacetylmethadol except levoalphacetylmethadol (9603).
Normethadone (9635) ..................
Norpipanone (9636) .....................
3-Methylfentanyl (9813) ................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
1-Phenylcyclohexylamine (7460)
Phencyclidine (7471) ....................
Phenylacetone (8501) ..................
1Piperidinocyclohexanecarbonitrile (8603).
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
Ethylmorphine (9190) ...................
Hydrocodone (9193) .....................
Isomethadone (9226) ...................
Meperidine (9230) ........................
Meperidine intermediate-A (9232)
Merperidine intermediate-B (9233)
Methadone (9250) ........................
Methadone intermediate (9254) ...
Dextropropoxyphene,bulk, (nondosageforms) (9273).
Morphine (9300) ...........................
Normorphine (9313) .....................
Thebaine (9333) ...........................
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
Fentanyl (9801) ............................
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
small quantities of the listed controlled
substances to produce isotope labeled
standards for drug testing and analysis.
Any other such applicant and any
person who is presently registered with
E:\FR\FM\05JYN1.SGM
05JYN1
36728
Federal Register / Vol. 72, No. 128 / Thursday, July 5, 2007 / Notices
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, D.C. 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than September 4, 2007.
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12976 Filed 7–3–07; 8:45 am]
BILLING CODE 4410–09–P
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12955 Filed 7–3–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
sroberts on PROD1PC70 with NOTICES
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 2, 2007,
Amri Rensselaer, Inc., 33 Riverside
Avenue, Rensselaer, New York 12144,
made application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Lisdexamfetamine (1205), a basic class
of controlled substance listed in
schedule II.
The company plans to manufacture
the listed controlled substance in bulk
for sales to its customer.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than September 4, 2007.
VerDate Aug<31>2005
18:43 Jul 03, 2007
Jkt 211001
BILLING CODE 4410–09–P
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 8, 2007,
Austin Pharma LLC, 811 Paloma Drive,
Suite A, Round Rock, Texas 78664,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
I and II:
Drug
Manufacturer of Controlled
Substances; Notice of Application
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12978 Filed 7–3–07; 8:45 am]
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Alexandria, Virginia 22301; and must be
filed no later than September 4, 2007.
Schedule
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Alphamethadol (9605) ..................
Methadone (9250) ........................
Methadone Intermediate (9254) ...
Levo-alphacetylmethadol (9648) ..
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
I
I
I
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
In reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol as a synthetic
intermediate. This controlled substance
will be further synthesized to bulk
manufacture a synthetic THC (7370). No
other activity for this drug code is
authorized for this registration.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 2401 Jefferson Davis Highway,
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 8, 2007,
Boehringer Ingelheim Chemicals, Inc.,
2820 N. Normandy Drive, Petersburg,
Virginia 23805, made application by
letter to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of
Lisdexamfetamine (1205), a basic class
of controlled substance listed in
schedule II.
The company plans to qualify as a
bulk manufacturer of the above listed
controlled substance.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than September 4, 2007.
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12967 Filed 7–3–07; 8:45 am]
BILLING CODE 4410–09–P
E:\FR\FM\05JYN1.SGM
05JYN1
]]>Agencies
[Federal Register Volume 72, Number 128 (Thursday, July 5, 2007)]
[Notices]
[Pages 36727-36728]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-12976]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on May 18, 2007, Aldrich
Chemical Company, Inc., DBA Isotec, 3858 Benner Road, Miamisburg, Ohio
45342-4304, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the
basic class of controlled substance listed in schedule I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235)........................... I
Methcathinone (1237)....................... I
N-Ethylamphetamine (1475).................. I
N,N-Dimethylamphetamine (1480)............. I
Aminorex (1585)............................ I
Gamma Hydroxybutyric Acid (2010)........... I
Methaqualone (2565)........................ I
Ibogaine (7260)............................ I
Lysergic acid dethylamide (7315)........... I
Tetrahydrocannabinols (7370)............... I
Mescaline (7381)........................... I
2,5-Dimethoxyamphetamine (7396)............ I
3,4-Methylenedioxyamphetamine (7400)....... I
3,4-Methylenedioxy-N-ethylamphetamine I
(7404).
3,4-Methylenedioxymethamphetamine (7405)... I
4-Methoxyamphetamine (7411)................ I
Psilocybin (7437).......................... I
Psilocyn (7438)............................ I
N-Ethyl-1-phenylcyclohexylamine (7455)..... I
Dihydromorphine (9145)..................... I
Normorphine (9313)......................... I
Acetylmethadol (9601)...................... I
Alphacetylmethadol except levo- I
alphacetylmethadol (9603).
Normethadone (9635)........................ I
Norpipanone (9636)......................... I
3-Methylfentanyl (9813).................... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Methylphenidate (1724)..................... II
Amobarbital (2125)......................... II
Pentobarbital (2270)....................... II
Secobarbital (2315)........................ II
1-Phenylcyclohexylamine (7460)............. II
Phencyclidine (7471)....................... II
Phenylacetone (8501)....................... II
1-Piperidinocyclohexanecarbonitrile (8603). II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Benzoylecgonine (9180)..................... II
Ethylmorphine (9190)....................... II
Hydrocodone (9193)......................... II
Isomethadone (9226)........................ II
Meperidine (9230).......................... II
Meperidine intermediate-A (9232)........... II
Merperidine intermediate-B (9233).......... II
Methadone (9250)........................... II
Methadone intermediate (9254).............. II
Dextropropoxyphene,bulk, (non-dosageforms) II
(9273).
Morphine (9300)............................ II
Normorphine (9313)......................... II
Thebaine (9333)............................ II
Levo-alphacetylmethadol (9648)............. II
Oxymorphone (9652)......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture small quantities of the listed
controlled substances to produce isotope labeled standards for drug
testing and analysis.
Any other such applicant and any person who is presently registered
with
[[Page 36728]]
DEA to manufacture such a substance may file comments or objections to
the issuance of the proposed registration pursuant to 21 CFR
1301.33(a).
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Drug Enforcement
Administration, Office of Diversion Control, Federal Register
Representative (ODL), Washington, D.C. 20537, or any being sent via
express mail should be sent to Drug Enforcement Administration, Office
of Diversion Control, Federal Register Representative (ODL), 2401
Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed
no later than September 4, 2007.
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-12976 Filed 7-3-07; 8:45 am]
BILLING CODE 4410-09-P
